Barclays PLC Sellas Life Sciences Group, Inc. Transaction History
Barclays PLC
- $436 Billion
- Q2 2025
A detailed history of Barclays PLC transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Barclays PLC holds 172,803 shares of SLS stock, worth $330,053. This represents 0.0% of its overall portfolio holdings.
Number of Shares
172,803
Previous 172,803
-0.0%
Holding current value
$330,053
Previous $378,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding SLS
# of Institutions
86Shares Held
22.7MCall Options Held
1.3MPut Options Held
59.3K-
Vanguard Group Inc Valley Forge, PA6.65MShares$12.7 Million0.0% of portfolio
-
Marshall Wace, LLP London, X02.72MShares$5.19 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.2MShares$4.2 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA1.49MShares$2.85 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.13MShares$2.15 Million0.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $39.3M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...